title: Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.
abstract: The metabolic syndrome is a risk factor for the development of chronic kidney disease. Angiotensin II type 1 receptor blockers (ARBs) and thiazolidinediones (TZDs) provide renovascular protection, probably in the metabolic syndrome. However, the effect of both agents administered together in patients with metabolic syndrome remains to be determined. The aim of this study was to assess the effects of ARB plus TZD combination therapy in Zucker obese rats fed a high-protein diet, an animal model of metabolic syndrome and renal injury. Zucker obese rats were fed a high-protein diet (OHP; n=6), a high-protein diet containing candesartan, an ARB (OHP+C; n=6), or a high-protein diet containing both candesartan and pioglitazone (OHP+CP; n=6) for 12 weeks. Systolic blood pressure and urinary protein excretion were measured throughout the study, and renal histology and immunohistochemistry were assessed at 12 weeks. OHP rats developed hypertension (157+/-4 mmHg) and proteinuria (178+/-44 mg/d), and these conditions were significantly ameliorated by candesartan (to 143+/-3 mmHg and 84+/-25 mg/d, respectively). Pioglitazone enhanced the antihypertensive and anti-proteinuric effects of candesartan (121+/-3 mmHg, 16+/-8 mg/d, respectively). Histologically, candesartan ameliorated glomerulosclerosis, podocyte injury, interstitial fibrosis and monocyte/macrophage infiltration into the tubulointerstitium in the kidneys of OHP rats. Pioglitazone abrogated residual interstitial fibrosis in the kidneys of OHP+C rats. Our results suggested that pioglitazone augmented the antihypertensive, anti-proteinuric and possibly renal anti-fibrotic actions of candesartan in Zucker obese rats fed a high-protein diet. The combination therapy of ARB and TZD may protect against renal injury in patients with metabolic syndrome.
authors.affiliation: Division of Nephrology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.
authors.forename: Tamehachi
authors.initials: T
authors.lastname: Namikoshi
authors.forename: Naruya
authors.initials: N
authors.lastname: Tomita
authors.forename: Minoru
authors.initials: M
authors.lastname: Satoh
authors.forename: Yoshisuke
authors.initials: Y
authors.lastname: Haruna
authors.forename: Shinya
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Norio
authors.initials: N
authors.lastname: Komai
authors.forename: Tamaki
authors.initials: T
authors.lastname: Sasaki
authors.forename: Naoki
authors.initials: N
authors.lastname: Kashihara
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D001713:Biphenyl Compounds; D001794:Blood Pressure; D004044:Dietary Proteins / Q000494:pharmacology; D004357:Drug Synergism; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007150:Immunohistochemistry; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000453:epidemiology; D009765:Obesity / Q000453:epidemiology; D000077205:Pioglitazone; D051381:Rats; D011924:Rats, Zucker; D051436:Renal Insufficiency, Chronic / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control*; D012307:Risk Factors; D013777:Tetrazoles / Q000494:pharmacology*; D045162:Thiazolidinediones / Q000494:pharmacology*
chemical_list: D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D004044:Dietary Proteins; D007004:Hypoglycemic Agents; D013777:Tetrazoles; D045162:Thiazolidinediones; C081643:candesartan; D000077205:Pioglitazone